Allergy Therapeutics plc (AIM:AGY)
London · Delayed Price · Currency is GBP · Price in GBX 5.40
-0.58 (-9.70%)
Jul 27, 2026, 4:35 PM GMT
Allergy Therapeutics Ratios and Metrics
Market cap in millions GBP. Fiscal year is July - June.
Millions GBP. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 342 | 379 | 250 | 7 | 134 | 160 | |
Market Cap Growth | -10.32% | 51.72% | 3402.67% | -94.66% | -16.70% | 79.83% |
Enterprise Value | 358.62 | 426.23 | 267.83 | 28.27 | 123.67 | 131.34 |
Last Close Price | 0.05 | 0.08 | 0.05 | 0.01 | 0.21 | 0.25 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
PE Ratio | - | - | - | - | - | 58.14 |
Forward PE | - | 63.31 | 63.31 | 63.31 | 63.31 | 63.31 |
PEG Ratio | - | 5.65 | 5.65 | 5.65 | 5.65 | 5.65 |
PS Ratio | 5.97 | 6.88 | 4.52 | 0.12 | 1.84 | 1.90 |
PB Ratio | 80.48 | -13.44 | 33.95 | 1.74 | 3.54 | 3.31 |
P/TBV Ratio | 5505.36 | - | 73.49 | - | 4.08 | 3.86 |
P/FCF Ratio | - | - | - | - | - | 26.62 |
P/OCF Ratio | - | - | - | - | - | 18.68 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
EV/Sales Ratio | 6.26 | 7.74 | 4.85 | 0.47 | 1.70 | 1.56 |
EV/EBITDA Ratio | - | - | - | - | - | 16.09 |
EV/EBIT Ratio | - | - | - | - | - | 32.58 |
EV/FCF Ratio | - | - | - | - | - | 21.79 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Debt / Equity Ratio | 5.83 | -2.06 | 3.92 | 8.32 | 0.22 | 0.19 |
Debt / EBITDA Ratio | - | - | - | - | - | 1.37 |
Debt / FCF Ratio | - | - | - | - | - | 1.85 |
Net Debt / Equity Ratio | 3.92 | -1.68 | 2.46 | 5.15 | -0.26 | -0.60 |
Net Debt / EBITDA Ratio | -0.63 | -1.97 | -0.58 | -0.60 | 1.24 | -3.56 |
Net Debt / FCF Ratio | -0.45 | -1.51 | -0.51 | -0.63 | 0.59 | -4.83 |
Asset Turnover | 0.80 | 0.82 | 0.82 | 0.84 | 0.90 | 0.97 |
Inventory Turnover | 2.13 | 1.93 | 2.09 | 2.29 | 2.09 | 2.11 |
Quick Ratio | 0.70 | 0.76 | 1.10 | 1.18 | 1.72 | 2.55 |
Current Ratio | 1.13 | 1.28 | 1.78 | 1.81 | 2.35 | 3.17 |
Return on Equity (ROE) | 3375.73% | 385.20% | -673.72% | -205.72% | -31.93% | 6.25% |
Return on Assets (ROA) | -44.60% | -43.05% | -51.57% | -57.85% | -16.55% | 3.65% |
Return on Invested Capital (ROIC) | -153.49% | -87.66% | -137.19% | -154.22% | -56.46% | 16.55% |
Return on Capital Employed (ROCE) | -72.33% | -64.04% | -72.35% | -75.71% | -19.63% | 5.85% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Earnings Yield | - | - | - | - | - | 1.72% |
FCF Yield | - | - | - | - | - | 3.76% |
Buyback Yield / Dilution | -4.81% | -27.33% | -458.41% | -4.26% | 4.98% | -0.47% |
Total Shareholder Return | -4.81% | -27.33% | -458.41% | -4.26% | 4.98% | -0.47% |